Hospital Universitario La Paz
Hospital Universitario La Paz
Madrid, Spain75 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases, Infant, Premature, Diseases, Lung Injury, Ventilator-Induced Lung Injury, bronchopulmonary dysplasia, lung disorder, respiratory system disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT06897839 | |
| Follow-up in Gynecological Cancer Survivors | female reproductive organ cancer | Active, not recruiting | Not stated | 2026-10-07 | NCT03515993 | |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Cholangitis, Sclerosing, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Abnormalities, Digestive System Diseases, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, bile duct disorder, biliary atresia, biliary tract disorder, cholangitis, skin disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06553768 | |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-10-01 | NCT06016842 | |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-10-01 | NCT02227251 | |
| A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Infant, Newborn, Diseases, Muscular Disorders, Atrophic, X-linked disease, congenital, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease | Recruiting | Phase 3 | 2026-09-29 | NCT07587242 | |
| A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT05708235 | |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, autoimmune hemolytic anemia, warm type, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT07549698 | |
| Failing Epidural Analgesia During Labor | Breakthrough Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Recruiting | Not stated | 2026-09-18 | NCT07473609 | |
| Sacituzumab govitEcan in THYroid Cancers | Neoplasms by Histologic Type, carcinoma, differentiated thyroid carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Recruiting | Phase 2 | 2026-09-16 | NCT06235216 | |
| Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2 | Arrhythmias, Cardiac, Body Temperature Changes, Hypothermia, Out-of-Hospital Cardiac Arrest, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiac arrest, cardiovascular disorder, heart disorder, ventricular fibrillation | Recruiting | Not applicable | 2026-09-16 | NCT06025123 | |
| Safety of HRX215 in Patients After Minor and Major Liver Resection | Colorectal Carcinoma Liver Metastases; Liver Resection | Recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT06638502 | |
| A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma. | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Recruiting | Phase 1 / Phase 2 | 2026-08-31 | NCT07460986 | |
| A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) | CLOVES syndrome, Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Lymphatic Abnormalities, angiomatosis, angioosteohypertrophic syndrome, cardiovascular disorder, lymphatic system disorder, megalencephaly-capillary malformation-polymicrogyria syndrome, vascular disorder, vascular malformation | Recruiting | Phase 2 | 2026-08-25 | NCT06789913 | |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast Cancer | Recruiting | Phase 3 | 2026-08-24 | NCT06382948 | |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium adenocarcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-08-21 | NCT05548296 | |
| A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI | Complicated Urinary Tract Infection | Recruiting | Phase 2 | 2026-08-20 | NCT05826990 | |
| Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy | Spinal Curvatures, bone disorder, central nervous system disorder, motor neuron disorder, musculoskeletal system disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, scoliosis, spinal cord disorder, spinal muscular atrophy, vertebral column disorder | Recruiting | Not applicable | 2026-08-19 | NCT05866419 | |
| Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma | gastroesophageal adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-18 | NCT07763171 | |
| A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-08-12 | NCT04307576 | |
| A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT | DNA Virus Infections, Infections, adenoviridae infectious disease, viral infectious disease | Recruiting | Phase 3 | 2026-08-10 | NCT07387367 | |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, head and neck squamous cell carcinoma, intestinal disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-04 | NCT04083599 | |
| A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 3 | 2026-07-30 | NCT04194775 | |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-07-27 | NCT06095583 |